Sellas Life Sciences Group Inc Asset Resilience Ratio
Sellas Life Sciences Group Inc asset resilience ratio. Sellas Life Sciences Group Inc (SLS) has an Asset Resilience Ratio of 0.38% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Sellas Life Sciences Group Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sellas Life Sciences Group Inc (2007–2023)
Asset resilience ratio of Sellas Life Sciences Group Inc from 2007 to 2023. This chart shows how Sellas Life Sciences Group Inc's Asset Resilience Ratio has changed over time. See Sellas Life Sciences Group Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Sellas Life Sciences Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SLS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $100.00K | 0.38% |
| Total Liquid Assets | $100.00K | 0.38% |
Asset Resilience Insights
- Limited Liquidity: Sellas Life Sciences Group Inc maintains only 0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sellas Life Sciences Group Inc Industry Peers by Asset Resilience Ratio
Compare Sellas Life Sciences Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Sellas Life Sciences Group Inc Asset Resilience Ratio by Year (2007–2023)
Sellas Life Sciences Group Inc asset resilience ratio by year from 2007 to 2023. The table below shows the annual Asset Resilience Ratio data for Sellas Life Sciences Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.61% | $100.00K | $6.22 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $33.53 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $65.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $82.14 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $80.49 Million | -- |
| 2012-12-31 | 4.87% | $2.68 Million | $54.99 Million | -77.06pp |
| 2007-12-31 | 81.93% | $9.95 Million | $12.15 Million | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more